Repaglinide
Repaglinide is an oral diabetes medicine (a glinide) that helps adults with type 2 diabetes control blood sugar, along with diet and exercise.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 10 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Repaglinide (Prandin) is a short-acting mealtime medicine for adults with type 2 diabetes that tells the pancreas to release more insulin, so it works only while your insulin-making (beta) cells still function; on the U.S. market since about 2004 and available as a generic, it is usually an add-on or alternative rather than a first choice. Most people tolerate it well, though headache, cold-like symptoms and nausea or diarrhea can show up. The thing to watch for is low blood sugar, which can come on suddenly and dull your concentration behind the wheel, so take it only before meals you eat and check your glucose as directed.
Clinical pearls
- Gemfibrozil, a triglyceride medicine, must never be taken with repaglinide, and clopidogrel should be avoided if possible.
- Take it within 30 minutes before each meal, and if you skip a meal, skip that dose too.
- Clarithromycin, erythromycin and trimethoprim can raise repaglinide levels, so mention it whenever you are prescribed an antibiotic.
- Beta-blockers can mute the warning signs of low blood sugar, so check your glucose more often if you take one.
Patient information guide A plain-language walkthrough of Repaglinide, written from its FDA label.
What Repaglinide is used for
▾
Repaglinide is used for blood sugar control in one condition.
- Repaglinide tablets: type 2 diabetes in adults, along with diet and exercise.
- Not for type 1 diabetes or diabetic ketoacidosis.
How Repaglinide works
▾
Repaglinide closes certain potassium channels on the insulin-making beta cells of the pancreas. This triggers calcium to enter the cells, which causes insulin release. The effect depends on blood sugar and fades when sugar is low. It works mainly on pancreatic cells, with low affinity for heart and skeletal muscle.
Repaglinide dosage
▾
Repaglinide tablets are taken by mouth shortly before meals.
- Take within 30 minutes before a meal.
- Can be taken 2, 3 or 4 times a day, depending on how many meals you eat.
- If you skip a meal, skip that dose.
- Your prescriber adjusts the dose, usually waiting at least a week between changes. Follow your label.
Dosing details from the FDA-approved label
From the Repaglinide prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Patients whose HbA1c is less than 8% (starting dose)
- 0.5 mg orally before each meal
- Dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved
- Maximum: Dose range 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg
- At least one week should elapse to assess response after each dose adjustment; take within 30 minutes before meals; skip the dose if a meal is skipped
- Patients whose HbA1c is 8% or greater (starting dose)
- 1 or 2 mg orally before each meal
- Dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved
- Maximum: Dose range 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg
- At least one week should elapse to assess response after each dose adjustment; may be dosed 2, 3, or 4 times a day in response to changes in meal pattern
- Patients with severe renal impairment (CrCl = 20 – 40 mL/min)
- Initiate at 0.5 mg orally before each meal
- Gradually titrate the dose, if needed to achieve glycemic control
- Severe renal impairment (CrCl = 20 – 40 mL/min)
- Patients who experience hypoglycemia
- The dose of repaglinide tablets should be reduced
- Patients taking concomitant clopidogrel (if use cannot be avoided)
- Initiate at 0.5 mg before each meal
- Maximum: Do not exceed a total daily dose of 4 mg
Read the label’s full dosing text
2 DOSAGE & ADMINISTRATION • The recommended starting dose is 0.5 mg orally before each meal if HbA1c is less than 8%; and 1 or 2 mg orally before each meal if HbA1c is 8% or greater. ( 2.1 ) • The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. ( 2.1 ) • The patient’s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved. At least one week should elapse to assess response after each dose adjustment. ( 2.1 ) • Instruct patients to skip the dose of repaglinide tablets if a meal is skipped. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced. ( 2.1 ; 5.1 ) • Instruct patients to take repaglinide tablets within 30 minutes before meals. ( 2.1 ) • In patients with severe renal impairment (CrCl = 20 – 40 mL/min), recommended starting dose is 0.5 mg orally before each meal. ( 2.2 ) • Dose modifications are required when used concominantly with some medications. ( 2.3 , 7 ) 2.1 Recommended Dosage and Administration The recommended starting dose for patients whose HbA 1c is less than 8% is 0.5 mg orally before each meal. For patients whose HbA 1c is 8% or greater the starting dose is 1 or 2 mg orally before each meal. The recommended dose range is 0.5 mg to 4 mg before meals, with a maximum daily dose of 16 mg. The patient’s dose should be doubled up to 4 mg with each meal until satisfactory glycemic control is achieved. At least one week should elapse to assess response after each dose adjustment. Instruct patients to take repaglinide tablets within 30 minutes before meals. Repaglinide tablets may be dosed 2, 3, or 4 times a day in response to changes in the patient’s meal pattern. In patients who skip meals, instruct patients to skip the scheduled dose of repaglinide tablets to reduce the risk of hypoglycemia. In patients who experience hypoglycemia, the dose of repaglinide tablets should be reduced [see Warnings and Precautions ( 5.1 )]. 2.2 Patients with Severe Renal Impairment In patients with severe renal impairment (CrCl = 20 – 40 mL/min) initiate repaglinide tablets 0.5 mg orally before each meal. Gradually titrate the dose, if needed to achieve glycemic control.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Repaglinide side effects
▾
The most common side effects in studies were:
Common side effects
- Low blood sugar (hypoglycemia)
- Upper respiratory infection
- Headache
- Sinus infection (sinusitis)
- Joint pain (arthralgia)
- Nausea
- Diarrhea
- Back pain
When to get medical help
- Call your doctor if you have low blood sugar symptoms, especially if they happen often. Severe low blood sugar can cause seizures and can be life-threatening.
- Get emergency help for severe low blood sugar with confusion, passing out or seizure.
- Tell your doctor if you feel chest pain or other heart symptoms, especially if you also use NPH insulin.
- Let your doctor know if you notice swelling or new heart failure signs while also taking a thiazolidinedione (pioglitazone or rosiglitazone).
Severe low blood sugar is the main serious reaction. Heart-related events were also reported, so report chest pain to your doctor.
Repaglinide warnings and precautions
▾
- Low blood sugar can be severe, causing seizures and rarely death. It can impair driving and machine safety.
- Higher risk with meal changes, activity changes, other diabetes drugs, and kidney or liver problems.
- Not indicated for use with NPH insulin. More heart ischemia events were seen in that combination.
- No conclusive evidence that it lowers heart and blood vessel complications.
- With thiazolidinediones, swelling and heart failure were reported in a few patients with prior coronary artery disease.
Repaglinide interactions
▾
Many drugs change repaglinide levels or blood sugar.
- Gemfibrozil: contraindicated, as it greatly raises repaglinide levels.
- Clopidogrel: avoid, since it raises levels several-fold.
- Cyclosporine: limits the daily dose.
- CYP3A4/CYP2C8 inhibitors: may require lower doses.
- Inducers like rifampin, barbiturates, carbamazepine: may require higher doses.
- Drugs that raise low blood sugar risk or lessen repaglinide's effect: may need dose changes and more glucose checks.
- Beta-blockers, clonidine, guanethidine, reserpine: can mask low blood sugar signs.
Interactions listed in the FDA-approved label
From the Repaglinide prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Gemfibrozil: Gemfibrozil significantly increased repaglinide tablets exposures by 8.1 fold. Do not administer repaglinide tablets to patients receiving gemfibrozil (contraindicated).
- Clopidogrel: Clopidogrel increased repaglinide tablets exposures by 3.9-5.1 fold. Avoid concomitant use; if it cannot be avoided, initiate at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg. Increased frequency of glucose monitoring may be required.
- Cyclosporine: Cyclosporine increased low dose repaglinide exposures by 2.5 fold. Limit daily maximum dose to 6 mg; increased frequency of glucose monitoring may be required.
- CYP2C8 and CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, erythromycin, trimethoprim, gemfibrozil, montelukast, deferasirox, clopidogrel): Drugs known to inhibit CYP3A4 or CYP2C8 may require repaglinide dose reductions when co-administered. Dose reductions and increased frequency of glucose monitoring may be required.
- CYP2C8 and CYP3A4 inducers (e.g., rifampin, barbiturates, carbamazepine): Drugs that induce the CYP3A4 and/or 2C8 enzyme systems may require repaglinide dose increases when co-administered. Dose increases and increased frequency of glucose monitoring may be required.
- Drugs that may increase the risk of hypoglycemia (e.g., antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, MAOIs, NSAIDs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs, sulfonamide antibiotics): These drugs may increase the risk of hypoglycemia. Dose reductions and increased frequency of glucose monitoring may be required.
- Drugs that may decrease the blood glucose lowering effect of repaglinide (e.g., atypical antipsychotics, calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents, thyroid hormones): These drugs may decrease the blood glucose lowering effect of repaglinide tablets. Dose increases and increased frequency of glucose monitoring may be required.
- Drugs that may blunt signs and symptoms of hypoglycemia (beta-blockers, clonidine, guanethidine, reserpine): These drugs may blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
Read the label’s full interactions text
7 DRUG INTERACTIONS Clinically Important Drug Interactions with Repaglinide Tablets Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with repaglinide tablets and instructions for preventing or managing them. Table 3: Clinically Important Drug Interactions with Repaglinide Tablets Gemfibrozil Clinical Impact: Gemfibrozil significantly increased repaglinide tablets exposures by 8.1 fold [see Clinical Pharmacology (12.3) ]. Intervention: Do not administer repaglinide tablets to patients receiving gemfibrozil [see Contraindications (4) ] . Clopidogrel Clinical Impact: Clopidogrel increased repaglinide tablets exposures by 3.9-5.1 fold [see Clinical Pharmacology (12.3) ] Intervention: Avoid concomitant use of repaglinide tablets with clopidogrel. If concomitant use cannot be avoided, initiate repaglinide tablets at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg [see Dosage and Administration (2.3) ] . Increased frequency of glucose monitoring may be required during concomitant use. Cyclosporine Clinical Impact: Cyclosporine increased low dose repaglinide exposures by 2.5 fold [see Clinical Pharmacology (12.3) ] Intervention: Daily maximum repaglinide tablets dose should be limited to 6 mg, and increased frequency of glucose monitoring may be required when repaglinide tablets are co-administered with cyclosporine. CYP2C8 and CYP3A4 Inhibitors Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co‑administered. Examples: Drugs that are known to inhibit CYP3A4 include antifungal agents (ketoconazole, itraconazole) and antibacterial agents (clarithromycin, erythromycin). Drugs that are known to inhibit CYP2C8 include trimethoprim, gemfibrozil, montelukast, deferasirox, and clopidiogrel.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Repaglinide
▾
- Do not use with gemfibrozil or with known allergy to repaglinide or its ingredients.
- Not for type 1 diabetes or diabetic ketoacidosis.
- Severe kidney impairment: lower starting dose.
- Liver impairment: use cautiously.
- Breastfeeding: not recommended.
- Pregnancy: discuss with your doctor.
- Children: safety and effectiveness not established.
- Older adults: some may be more sensitive.
Repaglinide overdose
▾
Too much repaglinide can cause severe low blood sugar, including coma, seizure or other neurologic problems. These are medical emergencies needing immediate hospitalization. Milder symptoms are treated with oral glucose and adjustments to dose or meals. Close monitoring for at least 24 to 48 hours is advised because low blood sugar can return.
What Repaglinide does in the body
▾
Repaglinide lowers blood sugar in proportion to the dose. Insulin levels rise after meals and return toward baseline before the next meal. Most of the fasting blood sugar lowering was seen within 1 to 2 weeks.
How your body processes Repaglinide
▾
Repaglinide is absorbed well, and levels peak within about 1 hour. Its half-life is about 1 hour. Taking it with food lowers peak levels somewhat. The liver fully breaks it down using CYP2C8 and CYP3A4 enzymes, and the metabolites do not lower blood sugar. About 90% leaves in the stool and about 8% in urine. Liver disease raises levels, and severe kidney impairment also raises them.
How to store Repaglinide
▾
Store at 20° to 25°C (68° to 77°F) . Protect from moisture. Dispense in tight containers with safety closures.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Repaglinide
256 supplements and herbal products have documented interactions with Repaglinide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 2
- Moderate · 215
- Minor · 39
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Repaglinide has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Repaglinide: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Repaglinide — the kind of thing our pharmacy team would talk through with you at the counter.
What is repaglinide for?
▾
When should I take it?
▾
What side effects should I expect?
▾
What should I do if I feel shaky or low?
▾
Can I take it with my other medicines?
▾
Is it safe if I'm pregnant or breastfeeding?
▾
Is Repaglinide available over the counter?
▾
When was Repaglinide first available?
▾
Who makes Repaglinide?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Repaglinide on HelloPharmacist
Repaglinide forms and strengths (how it comes)
Repaglinide is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Repaglinide tablets are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Repaglinide tablets are not for type 1 diabetes or diabetic ketoacidosis.
- Repaglinide tablets are taken by mouth within 30 minutes before meals.
- Repaglinide tablets should be skipped if you skip a meal.
- Repaglinide tablets may be taken 2, 3 or 4 times a day depending on your meal pattern.
Repaglinide on the U.S. market: products, makers and brands
How Repaglinide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
7 companies list 20 Repaglinide product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1997. Brand names on the directory include Prandin; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (8) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Repaglinide is used (Medicaid data)
A general measure of how commonly Repaglinide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Repaglinide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Repaglinide prescribed? Of the 1,601 medications we measure, Repaglinide ranks #701 by Medicaid prescriptions — more than 56% of them.
Utilization by Repaglinide product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
repaglinide 1 MG Oral Tablet Most dispensed
Summed across the 3 of 26 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200256
repaglinide 2 MG Oral Tablet
Summed across the 4 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200258
repaglinide 0.5 MG Oral Tablet
Summed across the 3 of 23 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200257
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Repaglinide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 10 of 73 listed Repaglinide NDCs with Medicaid activity.
Compare Repaglinide products
A representative set of FDA-listed product records for Repaglinide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 1 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 0.5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 1 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 2 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 0.5 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 1 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 2 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 0.5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 1 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 2 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 1 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 2 mg | Oral | Macleods Pharmaceuticals Limited | ANDA | View NDC → |
| 0.5 mg | Oral | NorthStar RxLLC | ANDA | View NDC → |
| 1 mg | Oral | NorthStar RxLLC | ANDA | View NDC → |
| 2 mg | Oral | NorthStar RxLLC | ANDA | View NDC → |
| 0.5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 1 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 2 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
Showing 20 of 20 products — FDA National Drug Code Directory. See every product, package size and price: browse all 20 Repaglinide NDCs →
Repaglinide side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Repaglinide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Repaglinide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Repaglinide FDA approval history
How Repaglinide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Repaglinide recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Repaglinide recalls since July 2021.
✅No Repaglinide recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 73044 1 dose form · 3 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 373759In current FDA listings
Look up RxCUI 73044 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Repaglinide supply and shortage status
Whether Repaglinide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Repaglinide costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 0.5 mg | $0.077 per tablet | NDC details & price history |
| Tablet · Oral | 1 mg | $0.099 per tablet | NDC details & price history |
| Tablet · Oral | 2 mg | $0.092 per tablet | NDC details & price history |
| Tablet | 0.5 mg | $0.077 per tablet | NDC details & price history |
| Tablet | 1 mg | $0.099 per tablet | NDC details & price history |
| Tablet | 2 mg | $0.092 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Repaglinide brand names
Repaglinide is sold under one brand name in the FDA directory — Prandin. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Repaglinide: manufacturers and labelers
7 companies list Repaglinide products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Aurobindo Pharma Limited, Chartwell RX, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Repaglinide drug class (RxNorm)
Repaglinide belongs to the Glinide class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Repaglinide page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. American Health Packaging is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →